Oncology Financial Statements From 2010 to 2025

TOI Stock  USD 1.00  0.01  0.99%   
Oncology Institute financial statements provide useful quarterly and yearly information to potential Oncology Institute investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Oncology Institute financial statements helps investors assess Oncology Institute's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Oncology Institute's valuation are summarized below:
Gross Profit
55.4 M
Profit Margin
(0.20)
Market Capitalization
76.3 M
Enterprise Value Revenue
0.3669
Revenue
361.1 M
We have found one hundred twenty available trending fundamental ratios for Oncology Institute, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Oncology Institute recent fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The Oncology Institute's current Enterprise Value is estimated to increase to about 494.9 M, while Market Cap is projected to decrease to under 164.4 M.

Oncology Institute Total Revenue

226.56 Million

Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 8.2 M or Selling General Administrative of 139.3 M, as well as many indicators such as Price To Sales Ratio of 0.51, Dividend Yield of 0.0235 or PTB Ratio of 2.88. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

Oncology Institute Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding68.4 M84.8 M47.3 M
Slightly volatile
Total Assets176.4 M240.6 M109.6 M
Slightly volatile
Other Current Liabilities11.2 M15.5 M7.5 M
Slightly volatile
Total Current Liabilities30.1 M40 M20.6 M
Slightly volatile
Total Stockholder Equity78.4 M65.6 M55 M
Slightly volatile
Other Liabilities6.7 MM8.4 M
Pretty Stable
Property Plant And Equipment Net48.4 M46.1 M11.8 M
Slightly volatile
Accounts Payable13.4 M16.6 M10.7 M
Slightly volatile
Cash37.5 M38.5 M16.8 M
Slightly volatile
Non Current Assets Total70.9 M75.6 M50.5 M
Slightly volatile
Non Currrent Assets Other323.5 K645.1 K207.5 K
Slightly volatile
Other Assets279.8 K548.5 K200.2 K
Slightly volatile
Cash And Short Term Investments61.5 M95.3 M28.6 M
Slightly volatile
Net Receivables30 M49.3 M21.8 M
Slightly volatile
Good Will6.2 M6.5 M14.1 M
Pretty Stable
Liabilities And Stockholders Equity176.4 M240.6 M109.6 M
Slightly volatile
Non Current Liabilities Total67.9 M135 M34.1 M
Slightly volatile
Inventory8.3 M15.7 MM
Slightly volatile
Other Current Assets5.7 M4.7 M2.7 M
Slightly volatile
Other Stockholder Equity140.2 M233.6 M63.2 M
Slightly volatile
Total Liabilities98 M175 M54.6 M
Slightly volatile
Property Plant And Equipment Gross55.8 M53.2 M13.5 M
Slightly volatile
Total Current Assets105.5 M165 M59.1 M
Slightly volatile
Capital Stock6.8 K7.2 K35.1 M
Slightly volatile
Non Current Liabilities Other312.1 K328.5 K2.2 M
Pretty Stable
Net Working Capital75.5 M125 M38.6 M
Slightly volatile
Intangible Assets15.3 M16.1 M20.3 M
Slightly volatile
Common Stock6.3 K9.2 K3.1 K
Slightly volatile
Property Plant Equipment10.3 M9.8 M3.7 M
Slightly volatile
Short and Long Term Debt Total144.5 M137.6 M40.1 M
Slightly volatile
Current Deferred Revenue466 K490.5 K2.5 M
Slightly volatile
Long Term Debt63.8 M99.8 M30.2 M
Slightly volatile
Short and Long Term Debt156.5 K164.7 K3.7 M
Slightly volatile
Short Term Debt4.8 M7.3 M5.2 M
Very volatile
Warrants368 M414 M451.4 M
Slightly volatile
Common Stock Total Equity4.2 K8.1 K2.1 K
Slightly volatile
Capital Surpluse194.5 M214.2 M174.4 M
Slightly volatile

Oncology Institute Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.8 M6.8 M2.5 M
Slightly volatile
Interest Expense8.2 M7.8 M1.7 M
Slightly volatile
Selling General Administrative139.3 M132.6 M45.1 M
Slightly volatile
Total Revenue226.6 M372.9 M171.3 M
Slightly volatile
Gross Profit45 M68.5 M35.6 M
Slightly volatile
Other Operating Expenses263.4 M461.4 M189.3 M
Slightly volatile
Cost Of Revenue181.5 M304.4 M135.7 M
Slightly volatile
Total Operating Expenses81.9 M157.1 M53.6 M
Slightly volatile
Reconciled Depreciation3.8 M6.3 M2.5 M
Slightly volatile
Selling And Marketing Expenses33.3 M37.4 M40.8 M
Slightly volatile

Oncology Institute Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow25.2 M16.1 M11.2 M
Slightly volatile
Depreciation3.8 M6.8 M2.5 M
Slightly volatile
Capital ExpendituresM5.3 M1.9 M
Slightly volatile
End Period Cash Flow31.4 M38.5 M15.1 M
Slightly volatile
Stock Based Compensation15.5 M20.5 M6.7 M
Slightly volatile
Cash Flows Other Operating6.9 M6.6 M1.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.510.532.173
Slightly volatile
Dividend Yield0.02350.02650.0289
Slightly volatile
PTB Ratio2.883.0311.6555
Slightly volatile
Days Sales Outstanding34.143.4737.6366
Slightly volatile
Book Value Per Share0.830.70.7885
Slightly volatile
Average Payables8.6 M9.7 M10.6 M
Slightly volatile
Stock Based Compensation To Revenue0.04590.04940.0242
Slightly volatile
Capex To Depreciation0.580.70.6681
Pretty Stable
PB Ratio2.883.0311.6555
Slightly volatile
EV To Sales0.80.843.0839
Slightly volatile
Inventory Turnover29.2722.2529.6816
Slightly volatile
Days Of Inventory On Hand11.5416.9812.652
Slightly volatile
Payables Turnover12.1916.5114.4977
Pretty Stable
Sales General And Administrative To Revenue0.00130.00150.0016
Slightly volatile
Capex To Revenue0.00950.01270.0089
Slightly volatile
Cash Per Share0.641.010.3746
Slightly volatile
Payout Ratio1.661.872.0381
Slightly volatile
Days Payables Outstanding28.2722.8825.7669
Very volatile
Intangibles To Total Assets0.130.140.4589
Slightly volatile
Current Ratio2.613.712.3167
Slightly volatile
Receivables Turnover9.858.699.8895
Slightly volatile
Graham Number4.183.981.6962
Slightly volatile
Shareholders Equity Per Share0.830.70.7885
Slightly volatile
Debt To Equity1.981.890.7192
Slightly volatile
Capex Per Share0.0330.05570.0331
Slightly volatile
Average Receivables12.8 M14.4 M15.7 M
Slightly volatile
Revenue Per Share2.733.963.6642
Slightly volatile
Interest Debt Per Share1.621.540.4145
Slightly volatile
Debt To Assets0.540.510.2519
Slightly volatile
Operating Cycle45.6460.4550.2886
Slightly volatile
Price Book Value Ratio2.883.0311.6555
Slightly volatile
Days Of Payables Outstanding28.2722.8825.7669
Very volatile
Dividend Payout Ratio1.661.872.0381
Slightly volatile
Company Equity Multiplier1.843.31.832
Slightly volatile
Long Term Debt To Capitalization0.320.540.2707
Slightly volatile
Total Debt To Capitalization0.640.610.3545
Slightly volatile
Debt Equity Ratio1.981.890.7192
Slightly volatile
Quick Ratio2.393.362.0351
Slightly volatile
Net Income Per E B T1.121.150.9302
Slightly volatile
Cash Ratio0.90.870.5655
Slightly volatile
Cash Conversion Cycle25.0842.5425.3142
Slightly volatile
Days Of Inventory Outstanding11.5416.9812.652
Slightly volatile
Days Of Sales Outstanding34.143.4737.6366
Slightly volatile
Price To Book Ratio2.883.0311.6555
Slightly volatile
Fixed Asset Turnover8.849.3173.3411
Slightly volatile
Debt Ratio0.540.510.2519
Slightly volatile
Price Sales Ratio0.510.532.173
Slightly volatile
Asset Turnover1.971.782.2637
Slightly volatile
Gross Profit Margin0.220.210.2188
Slightly volatile
Price Fair Value2.883.0311.6555
Slightly volatile

Oncology Institute Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap164.4 M173 M509 M
Slightly volatile
Enterprise Value494.9 M272.1 M538.8 M
Slightly volatile

Oncology Fundamental Market Drivers

Cash And Short Term Investments82.9 M

Oncology Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Oncology Institute Financial Statements

Investors use fundamental indicators, such as Oncology Institute's revenue or net income, to determine how well the company is positioned to perform in the future. Although Oncology Institute's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue490.5 K466 K
Total Revenue372.9 M226.6 M
Cost Of Revenue304.4 M181.5 M
Stock Based Compensation To Revenue 0.05  0.05 
Capex To Revenue 0.01  0.01 
Revenue Per Share 3.96  2.73 
Ebit Per Revenue(0.27)(0.29)

Currently Active Assets on Macroaxis

When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.77)
Revenue Per Share
4.873
Quarterly Revenue Growth
0.229
Return On Assets
(0.19)
Return On Equity
(1.26)
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.